Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.

in hemodialysis patients with heparin-induced thrombocytopenia. Am J Nephrol 2001; 21: 226–231 2. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 2002; 28: 467–482 3. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846–851 4. Potzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86: 373–383 5. Willey ML, de Denus S, Spinler SA. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis. Pharmacotherapy 2002; 22: 492–499 6. Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialysers. Nephrol Dial Transplant 1999; 14: 2922–2926 7. Fischer KG, Liebe V, Hudek R, Piazolo L et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003; 89: 973–982 8. O’Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparininduced thrombocytopenia. Semin Dial 2003; 16: 61–67 9. Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004; 2: 339–357